On Tuesday, Shares of Becton, Dickinson and Co. (NYSE:BDX), lost -0.22% to $140.51.
Becton, declared its participation in the White House Forum on Antibiotic Stewardship and outlined multiple steps the company will take to assist combat drug resistant organisms.
The event brings together key Federal and private sector participants involved in the development, promotion and implementation of antibiotic stewardship activities to ensure the responsible use of antibiotics nationwide.
In support of the Forum, BD outlined multiple actions it plans to take over the next five years to assist combat drug resistant organisms and further promote antimicrobial stewardship. Among those commitments comprise:
Improve Diagnosis and Treatment
- Develop a new diagnostic test to rapidly detect Carbapenem Resistant Enterobacteriaceae (CRE)
- Create a pandemic sentinel system that comprises identification of CRE cases to enable timely intervention
- Deploy antimicrobial susceptibility tests (AST) to ensure the appropriate use of all accessible antibiotics.
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide.
Shares of EP Energy Corp (NYSE:EPE), inclined 3.74% to $ 13.31, during its last trading session.
EP Energy, declared the completion of its formerly declared tender offer to purchase for cash any and all of the outstanding 6.875% Senior Secured Notes due 2019 issued by EP Energy and its wholly-owned partner, Everest Acquisition Finance Inc., as co-issuer. The tender offer expired at 5:00pm, New York City time, on Wednesday, May 27, 2015.
EP Energy received tenders from the holders of $480,758,000 aggregate principal amount of the Notes, as stated by the tender agent, by the Expiration Time. EP Energy has accepted for purchase all of the Notes validly tendered.EP Energy has paid total consideration of $1,037.88 per $1,000 principal amount of the Notes, plus any accrued and unpaid interest from the last interest payment date to, but not counting, the payment date.
EP Energy Corporation, an independent exploration and production company, acquires and develops unconventional onshore oil and natural gas properties in the United States.
At the end of Tuesday’s trade, Shares of Intrexon Corp (NYSE:XON), gained 1.03% to $42.31.
Intrexon, declared the appointment of Olivier R. Jarry, M.B.A, as Senior Vice President, Consumer Sector. Mr. Jarry will lead the expansion of Intrexon’s programs employing novel biologically-based solutions in products and applications for consumer markets.
Mr. Jarry brings to Intrexon over 30 years of experience in leading global life sciences and consumer health executive roles. Most recently Mr. Jarry founded and served as Managing Partner of Imagiance LLC, a planned, administration and transaction advisory firm focusing on optimizing portfolio value and integrated care for biotechnology and medical technology companies. Preceding to Imagiance, he was Head of Strategy, Operations, Market Access in Emerging Markets at Bristol-Myers Squibb, where he led commercial operations for a $1 billion dollar division. Mr. Jarry also held executive roles at Bayer Healthcare as the Global Business Unit Head for Bayer Diabetes Care, coordinating the successful launch of five new products, and at Novartis, Danone, and Accenture. He holds an M.B.A. from the TRIUM Global Executive Program.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
Finally, Veeva Systems Inc (NYSE:VEEV), ended its last trade with 2.08% gain, and close at $ 26.97.
Veeva Systems is among the top three most preferred life sciences software vendors, according to IDC Health Insights’ Leading Indicators in Life Sciences IT Spending Survey, which measures planned investments for 2015. This is the third year that Veeva has been among the top ten vendors, and has been steadily increasing its standing among life sciences executives over the past three years - jumping to 3rd most preferred provider from 8th two years ago.
Veeva delivers industry cloud software solutions to assist life sciences companies achieve their most pressing planned objectives - bringing drugs to market faster and more efficiently, maximizing revenues, and maintaining compliance with government regulations. Veeva was the only industry cloud vendor to top the list.
Veeva Systems Inc. provides cloud-based software solutions for the life sciences industry in North America, Europe, the Asia Pacific, and Latin America. Its solutions comprise Veeva CRM, a customer relationship administration solution that allows pharmaceutical and biotechnology companies to market and sell compliantly to physicians, other healthcare professionals, and healthcare organizations through multiple touch points, counting face-to-face, email, and online; and Veeva Vault, a cloud-based content administration and partnership solution for its customers to manage content-centric processes in various departments within a life sciences company, counting clinical trials, regulatory submissions, quality administration, manufacturing, medical, sales, and marketing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
